
AstraZeneca Korea receives approval for Imfinzi in limited-stage small cell lung cancer
AstraZeneca Korea said Imfinzi (ingredient: durvalumab) has won regulatory approval from the Ministry of Food and Drug Safety (MFDS) to treat limited-stage small cell lung cancer (LS-SCLC) as a monotherapy following platinum-based chemoradiotherapy (CRT). …